To include your compound in the COVID-19 Resource Center, submit it here.
Shire plc (LSE:SHP; NASDAQ:SHPG) said SHP616 met the primary endpoint in the Phase III SAHARA trial to treat symptomatic hereditary angioedema in patients ages 12 and older. SHP616 is
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury